Although treatment with the EGFR-inhibitor cetuximab improves OS in HNSCC patients, therapeutic resistance poses a challenging problem and limits the success of effective anti-EGFR cancer therapies in the clinic (24). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.